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Abstract A series of variants of the neuroactive 17-residue
Q-carboxyglutamate-(Gla)-containing polypeptide, conantokin-G
(con-G), were synthesized with the intention of determining those
features that were important for its N-methyl-D-aspartate
(NMDA) receptor-targeted antagonist activity and for adoption
of its divalent cation-dependent K-helical conformation. Employ-
ing the binding of [3H]dizolcipine (MK-801) as an assay for open
receptor ion channels in rat brain membranes, which displays
inhibition by con-G (IC50 = 0.48 WM), it was found that
replacement by an Ala residue of Gla4 led to complete
inactivation of the peptide, whereas a similar replacement of
Gla3 resulted in a 20-fold decreased potency. Ala substitutions
for Gla10 and Gla14 did not substantially affect [3H]MK-801
binding. This same substitution at Gla7 appeared to slightly
enhance binding. Ala replacements of non-Gla residues demon-
strated that four of them, viz. Glu2, Leu5, Gln9, and Ile12,
possessed at least 200-fold decreases in inhibitory potency,
whereas similar replacements at Gly1, Leu11, and Arg13 resulted
in peptides with 8- to 12-fold increases in the IC50 values. The
remaining amino acid residues tested in the single Ala replace-
ment series showed no significant changes in the inhibitory
characteristics of wild-type con-G. Additional studies with
carboxyl-terminal truncated peptides revealed that the carbox-
yl-terminal 4 amino acids were unimportant for this activity.
There was no strict correlation of inhibition of [3H]MK-801
binding with the ability of these peptides to form cation-
dependent K-helices. Peptides with notably low K-helical content
in the presence of these cations were lacking at least one, or both,
of Gla10 and Gla14. Con-G[Gla3;4;7;10;14E] and con-
G[Gla7;10;14E] were the only peptides that remained in a
completely random conformation upon metal ion addition.
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1. Introduction
The conantokins are a group of peptides isolated from the
venoms of Conus snails. The two most widely investigated
members of this class are conantokin-G (con-G) and conan-
tokin-T (con-T), peptides possessing 17 and 21 amino acids,
respectively. Contained in these peptides is the amino acid
Q-carboxyglutamate (Gla), at levels of 5 and 4 residues,
respectively [1,2]. This structural feature allows the peptides
to interact with a variety of metal cations [3^5]. The binding
of divalent cations, such as Ca2, Mg2, and Zn2, to con-G
leads to a conformational change of the peptide, from a ran-
dom structure to an end-to-end K-helix [3,4,6,7]. Similarly,
adoption of a full K-helical conformation is found in con-T
as a result of binding of these cations [8]. However, in this
case the change is less dramatic, since apo-con-T already pos-
sesses a high K-helical molecular subpopulation [9].
The N-methyl-D-aspartate (NMDA) receptor is a subclass
of ionotropic glutamate-dependent receptors that is widely
distributed in the mammalian CNS. Glutamate and glycine
are coagonists of the Ca2-permeable ion channel of this re-
ceptor [10,11], with polyamines among the agents displaying
allosteric stimulation [12]. Abnormal activation of the ion
channel has been associated with a variety of neuropatholog-
ical states, such as acute neuronal death after ischemic stroke
[13], and Ca2-related neurodegeneration in Parkinson’s [14]
and Alzheimer’s [15] diseases.
In the NMDA receptor system con-G and con-T speci¢cally
function as non-competitive inhibitors of ion £ow through
NMDA receptors. These peptides inhibit in a non-competitive
manner polyamine-stimulated dizolcipine (MK-801) binding
in rat brain membranes [8,16] with an IC50 W500 nM, attenu-
ate the NMDA-stimulated rise in neuronal intracellular Ca2
(IC50W2 WM) [2], decrease the NMDA-stimulated cGMP lev-
els in rat cerebellar granule neurons (IC50=77^177 nM) [17],
and inhibit glutamate-induced neurotoxicity [16]. The mecha-
nisms of the inhibitory e¡ects of the peptides have been at-
tributed to their inhibition of the positive e¡ector roles of
spermine [16] and of glutamate and glycine [18,19].
Little is currently known regarding the functions of speci¢c
amino acid side chains in elaborating the functional e¡ects of
the conantokins. Available data for both con-G and con-T
suggest that Gla10 and Gla14 are involved in stabilizing bind-
ing of the highest a⁄nity metal ion site, and in governing the
conformational change induced by multivalent cations [7,8].
The critical nature of Gla3 and Gla4 of con-T in inhibition of
the spermine-induced potentiation of the binding of MK-801
to open ion channels of the NMDA-receptor was established,
as well as the role of Gla4 in stabilizing the apo-con-T
K-helical conformation [8]. Similarly, with regard to con-G,
it was found that substitution at Gla3 and Gla4 reduced or
eliminated MK-801 binding function, while replacement of
Gla7, Gla10, and Gla14 did not a¡ect NMDA antagonist ac-
tivity of the resulting peptides [20]. In the light of these results,
a systematic investigation of the e¡ects of the structure-func-
tion relationships of these peptides is warranted. Thus, we
have synthesized an array of synthetic variants of con-G
and assessed the role of each amino acid in the NMDA re-
ceptor antagonist activity of con-G, as well as in the ability of
the peptides to adopt the metal cation-dependent K-helical
conformation. The results of this study are reported herein.
2. Materials and methods
2.1. Peptide synthesis, puri¢cation, and characterization
Syntheses of con-G (GEQQL5QQNQQ10LIRQK15SN-NH2)-based pep-
tides on a 0.1-mmol scale were accomplished on PAL resin supports
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(PerSeptive Biosystems, Framingham, MA, USA) using an Applied
Biosystems (Foster City, CA, USA) model 433A peptide synthesizer
as described previously [3]. The following side chain protecting groups
were used: O-tBu for Gla, Glu, and Ser; Trt for Asn and Gln; Pmc
for Arg; and Boc for Lys. The derivatized Gla was synthesized as
described previously [21]. Peptides were cleaved from the support
resin with 88% tri£uoroacetic acid in the presence of radical scav-
engers dithiothreitol and triisopropylsilane. Puri¢cations of the pep-
tides were accomplished by either FPLC chromatography on a Bio-
scale DEAE20 (Bio-Rad, Hercules, CA, USA) column or by reverse
phase HPLC on a semi-prep Vydac TP218510 (10U250 mm), as pre-
viously reported [3]. The target material was lyophilized, and desalted
on a Sephadex G-15 column (1.5U100 cm) that was equilibrated and
eluted with 0.1% NH4OH. The peptides were characterized by reverse-
phase HPLC and delayed extraction-matrix assisted laser desorption
ionization-time of £ight mass spectrometry (DE-MALDI-TOF) as
described [3].
The concentrations of the peptides were determined by amino acid
analysis and quantitative reverse phase-HPLC.
2.2. [3H]MK-801 binding assays
These assays were performed as previously described [8]. Adult
Sprague-Dawley rats were sacri¢ced by decapitation and forebrains
were removed and processed [16]. Inhibition assays were performed in
triplicate in a total volume of 500 Wl in 5 mM sodium-HEPES, 4.5 mM
Tris-Cl, pH 7.4, in the nominal absence of glutamate and glycine, with
varying concentrations of peptide. The ¢nal concentrations of
[3H]MK-801 and spermine were 5 nM and 50 WM, respectively. Bind-
ing was initiated by the addition of 300 Wl of membrane suspension,
containing 100^200 Wg protein. Incubations were carried out for 2 h at
room temperature. Assays were terminated by rapid ¢ltration over
Whatman GF/B ¢lters pretreated with 0.03% polyethyleneimine, using
a 24-well cell harvester (Brandel, Gaithersburg, MD, USA). Basal
[3H]MK-801 binding was de¢ned as the amount of radioligand bound
in the nominal absence of spermine. Observed enhancements in
[3H]MK-801 binding at 50 WM spermine were 60^300% over basal
values, depending on the membrane preparation. Non-speci¢c binding
was determined in the presence of 50 WM MK-801 and represented 5^
10% of total ligand bound in the presence of 50 WM spermine.
2.3. Circular dichroism (CD) spectroscopy
CD spectra of con-G analogues were collected at 25‡C in 10 mM
sodium borate/100 mM NaCl, pH 6.5, on an Aviv model 62DS spec-
trometer using a 1-cm pathlength cell. The peptide solutions and
bu¡ers used were treated with Chelex-100 resin prior to the experi-
ments to ensure that they contained no multivalent metal ions. CD
spectra of the peptides were acquired in 100% aqueous bu¡er with the
above composition, or with the addition of either 20 mM CaCl2 or
1.5 mM MgCl2. The peptide concentration was 35 WM. The K-helical
content was determined from mean residue ellipticities at 222 nm
using the empirical relationship fK= (3[Q]22232340)/30300 [22].
3. Results
To test the importance of amino acid side chains in the
properties of con-G, a series of con-G-based variant peptides
were synthesized. These included peptides with single amino
acid replacements to Ala of the ¢rst 14 amino-terminal resi-
dues, peptides that were truncated at the carboxyl-terminal
end at each of the amino acids between 11 and 15, and several
peptides in which one or more Gla residues were replaced
with Glu, Lys, or Pro, in addition to Ala. For purposes of
characterization of the puri¢ed peptides, their molecular
weights were determined by DE-MALDI-TOF. These values
are listed in Table 1.
The NMDA-receptor antagonist activity of each peptide
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Table 1
NMDA-Receptor antagonist and conformational properties of con-G analogues
Peptide Mol. wt.a IC50 (WM)b % K-helixc
Apo Ca2 Mg2
Con-G 2264.8 (2265.2) 0.48 þ 0.03 2 50 72
Con-G[G1A] 2278.1 (2278.7) 6.5 þ 1.3 0 32 58
Con-G[E2A] 2205.9 (2206.6) s 100 (0) 2 42 68
Con-G[Gla3A] 2159.4 (2162.7) 9.6 þ 1.5 5 31 44
Con-G[Gla4A] 2158.8 (2162.7) s 100 (0) 0 36 59
Con-G[L5A] 2224.9 (2222.5) s 100 (0) 0 35 57
Con-G[Q6A] 2206.9 (2207.6) 0.51 þ 0.05 0 35 57
Con-G[Gla7A] 2164.0 (2162.7) 0.12 þ 0.02 5 24 32
Con-G[Gla7K] 2218.8 (2219.8) 0.22 þ 0.03 10 32 38
Con-G[Gla7P] 2189.0 (2188.7) s 100 (0) 1 14 26
Con-G[N8A] 2223.2 (2221.6) 0.49 þ 0.05 2 44 72
Con-G[Q9A] 2206.3 (2207.6) s 100 (38)d 0 36 60
Con-G[Gla10A] 2162.0 (2162.7) 2.0 þ 0.3 7 14 31
Con-G[Gla10E] 2219.4 (2220.7) 1.7 þ 0.1 2 10 29
Con-G[L11A] 2223.8 (2222.5) 5.9 þ 1.3 0 37 62
Con-G[I12A] 2223.0 (2222.5) s 100 (15)d 0 28 57
Con-G[R13A] 2181.1 (2179.5) 3.4 þ 0.5 0 15 45
Con-G[Gla14A] 2163.6 (2162.7) 0.23 þ 0.03 11 21 39
Con-G[Gla10;14A] 2061.4 (2060.8) 0.71 þ 0.11 5 12 24
Con-G[Gla7;10;14E] 2132.9 (2132.9) 4.7 þ 0.6 2 2 3
Con-G[Gla3;4;7;10;14E] 2044.4 (2045.1) s 100 (0) 4 4 6
Con-G[1^15] 2064.3 (2063.5) 1.2 þ 0.08 0 27 48
Con-G[1^14] 1938.1 (1935.3) 5.9 þ 1.5 0 17 51
Con-G[1^13] 1763.6 (1762.3) 2.9 þ 0.3 0 4 18
Con-G[1^12] 1608.4 (1606.1) s 100 (30) 0 6 16
Con-G[1^11] 1492.6 (1492.9) s 100 (0) 0 5 17
aThe observed (and calculated) molecular weights as determined by DE-MALDI-TOF mass spectromentry.
bValues represent the peptide concentration needed to achieve 50% inhibition of the spermine potentiation of [3H]MK-801 binding to rat brain
membranes. Data are mean þ standard error of three experiments. The numbers in parentheses represent the % inhibition of [3H]MK-801 binding at
100 WM peptide.
cSecondary structure content of con-G analogues in the absence and presence of Ca2 and Mg2. K-Helicity values were determined by CD
measurements.
dThe inhibition reached 100% at suitably high concentrations of peptide.
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was measured with the [3H]MK-801 binding assay. This
NMDA receptor speci¢c open channel blocker has been
used widely as a radioligand in binding assays to monitor
the e¡ects of various modulators of the NMDA receptor
[23]. Conantokins have been shown to be capable of inhibiting
the spermine-enhanced [3H]MK-801 binding to rat brain
membranes in a dose-dependent manner [8,16]. Representative
plots of the inhibition of the spermine-induced phase of
[3H]MK-801 binding by wild-type con-G, con-G[Gla3A],
con-G[Gla4A] and con-G[R13A] are shown in Fig. 1. The
IC50 values obtained from data of this type for each peptide
are listed in Table 1.
Two out of the ¢ve Gla residues appear to play a signi¢cant
role in the bioactivity of con-G. The Ala replacement of Gla3
resulted in a peptide with 20-fold decreased inhibitory activity,
whereas the same replacement at Gla4 resulted in a peptide
that lacked inhibitory properties up to a concentration of
100 WM. Ala replacements at Gla7, Gla10, and Gla14 e¡ect
only small changes in the IC50 values.
Examination of single Ala replacements of non-Gla residues
demonstrated that four of them, viz., Glu2, Leu5, Gln9, and
Ile12, led to dramatic decreases of inhibitory potency. These
peptides showed less than 50% inhibition at their highest ex-
perimental concentrations (100 WM). Therefore, these ana-
logues are at least 200-fold less potent than con-G with re-
spect to inhibition of [3H]MK-801 binding. Ala replacements
of three additional residues, Gly1, Leu11, and Arg13 revealed
signi¢cant contributions to the inhibitory properties of con-G.
In these cases, Ala replacements resulted in peptides that dis-
played 8- to 12-fold increases in the IC50 values. The remain-
ing amino acid residues tested in the single Ala replacement
series showed no signi¢cant changes in the inhibitory charac-
teristics of wild-type con-G. These residues include Gln6 and
Asn8. Additional studies with carboxyl-terminal truncations
to peptides containing 15, 14, and 13 amino acids from the
amino-terminus and onward of con-G resulted in 2-fold, 12-
fold, and 6-fold increases in IC50 respectively. Further trunca-
tions to 12 or 11 residues resulted in at least 200-fold increases
in the IC50 values.
Two variants with multiple Gla to Glu replacements have
largely decreased antagonist activities, as revealed by this
same assay. The con-G variant, in which all ¢ve Gla residues
were altered to Glu, had a higher than detectable (E100 WM)
IC50. A similar analogue, with two Gla residues at positions 3
and 4, and Glu residues at Gla7, Gla10 and Gla14, possesses a
10-fold decreased potency as compared to con-G. A Gla to
Lys replacement at position 7 is well-tolerated. Moreover, this
peptide displays an IC50 value that is slightly lower than that
of wild-type con-G. This is similar to the behavior of con-
G[Gla7A]. However, a Pro substitution at Gla7 leads to a
greatly diminished potency.
Since con-G undergoes a large metal cation-induced con-
formational change, it is also relevant to examine the extent to
which this occurs with the synthetic variants. The secondary
structure of each variant was evaluated by CD spectroscopy,
both in the absence and presence of divalent cations. Fig. 2
illustrates the CD spectra of con-G, con-G[I12A], and
con-G[R13A]. Wild-type con-G as well as its analogues show
a random conformation in their cation-free apo forms. The
CD spectra of cation-bound peptides are characterized by
varying degrees of K-helicity, with the wild-type peptide dis-
playing more than 70% K-helix in the Mg2 bound form.
Table 1 summarizes the K-helical contents of con-G var-
iants in the apo, Ca2-bound and Mg2-bound states. All
apo-peptides possess none-to-very-low (6 11%) K-helicity.
Metal cation-bound peptides possess varying degrees of
K-helical secondary structure. Peptides with notably low
K-helical content in the presence of these cations are lacking
at least one, or both, Gla residues at positions 10 and 14.
Con-G[Gla3;4;7;10;14E] and con-G[Gla7;10;14E] are the only pep-
tides that remain in a completely random conformation upon
metal ion addition.
4. Discussion
Several amino acids contained in the primary structure of
con-G have been identi¢ed as contributors to its NMDA re-
ceptor inhibitory activity and replacement of these residues
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Fig. 2. CD spectra of con-G analogues. Spectra were recorded at
25‡C in 10 mM sodium-borate, pH 6.5, 100 mM NaCl, 0 or 1.5 mM
MgCl2. (F) Con-G, no Mg2 ; (a) con-G+Mg2 ; (R) con-
G[I12A]+Mg2 ; (+) con-G[R13A]+Mg2.
Fig. 1. Inhibition of the polyamine enhanced [3H]MK-801 binding
by con-G analogues. Assay results are presented in a normalized
form, 100% being bound ligand in the presence of spermine (50 WM)
and 0% being basal binding (no added spermine). Parameter values
were ¢t by non-linear regression using Microcal Origin software.
(E) Con-G; (a) con-G[Gla3A]; (b) con-G[Gla4A]; (F) con-G[R13A].
These representative experiments were repeated three times with
similar results.
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with Ala resulted in a signi¢cant reduction in the potency of
these variants. As seen from the data of Table 1, replacement
of any one of ¢ve residues by Ala, that includes Glu2, Gla4,
Leu5, Gln9, and Ile12, resulted in an at least 200-fold increase
in the IC50 value that is associated with the spermine-induced
stimulatory phase of [MK-801] binding to open channels of
the NMDA receptor. Another group of residues, viz. Gly1,
Gla3, Leu11, and Arg13, displayed more minor involvement in
function, in that their Ala variants reduced the inhibitory
potency of con-G by 8- to 20-fold. The remainder of the
residues directly tested, that included Gln6, Gla7, Asn8,
Gla10, and Gla14, did not show signi¢cant e¡ects on the
NMDA receptor inhibitory properties of con-G upon their
replacement by Ala as revealed by the spermine-induced
[3H]MK-801 binding assay.
These results indicated that amino-terminal residues were
heavily involved in this function of con-G, with lesser direct
involvement of carboxyl-terminal residues. Thus, a series of
carboxyl-terminal truncated variants of con-G were synthe-
sized and tested in this manner. The results (Table 1) showed
that there are no essential residues beyond Arg13, since con-G
containing only the amino-terminal 13 amino acids (con-G[1^
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Fig. 3. Role of side chains in the NMDA receptor antagonist action of con-G. This three dimensional structure of con-G was determined in
the presence of Mg2 by NMR spectroscopy [7]. Amino acids are color coded according to importance in NMDA receptor binding. Residues
in red: essential, when replaced by Ala, potency decreases by at least 200-fold. Residues in green: important, when replaced by Ala, potency
decreases by 8^20-fold. Residues in orange: not important, when replaced by Ala, potency does not decrease substantially.
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13]) still displayed an IC50 that was only 6-fold higher than
that of wild-type con-G. Con-G[1^12] and con-G[1^11]
proved to be insu⁄cient for inducing the e¡ects of con-G,
up to a 100-WM concentration of these peptides. The latter
is consistent with the requirement for Ile12 that was identi¢ed
by Ala replacement in a synthetic variant.
Two Gla residues, Gla10 and Gla14, that have previously
been identi¢ed to form the tight metal cation binding site,
do not appear to play a role in receptor binding. Ala replace-
ments of each of these residues do not result in signi¢cant
reductions in bioactivity. Signi¢cantly, however, in both of
these cases, metal ion binding is compromised substantially
[7], and K-helicity is decreased compared to con-G. Further,
replacing with Ala both Gla10 and Gla14 in the same con-G
variant (con-G[Gla10;14A]) causes a slight decrease in bioactiv-
ity, although K-helicity is signi¢cantly decreased. Also reveal-
ing are the results obtained with a variant peptide in which all
three Gla residues, at positions 7, 10, and 14, were replaced
with Glu (con-G[Gla7;10;14E]). This peptide possessed a 10-fold
increased IC50 in the [3H]MK-801 binding assay. Interestingly,
this same peptide displayed virtually no K-helicity, even in the
presence of multivalent cations. The con-G analog in which
all ¢ve Gla residues were replaced with Glu (con-
G[Gla3;4;7;10;14E]) did not retain bioactivity. This result pro-
vides additional evidence of the essential nature of Gla4, as
suggested by the Ala scan results. In this case, even a very
conservative variation at this residue severely compromises
bioactivity of the peptide.
The amino acid at position 7 is radically di¡erent in con-G
(Gla) and con-T (Lys), and this residue has been predicted to
stabilize the apo K-helix in con-T and destabilize such a con-
formation in con-G. In con-T, Lys7 can interact with both
Gla3, Gla4, and Gla10 forming essential (i, i+3 and (i,i+4)
interactions, thus stabilizing its K-helical structure. On the
other hand, the doubly negatively charged Gla7 in con-G
contributes to charge repulsion in the apo-form and to metal
binding/K-helix formation in the presence of multivalent cat-
ions [7], which is readily observed by CD measurements (Ta-
ble 1). Correspondingly, both Ala or Lys replacements of
Gla7 in con-G result in peptides with IC50 values slightly low-
er than that of the wild-type peptide. However, the Gla7Pro
replacement abolishes the bioactivity of con-G. This peptide
also possesses a low K-helical content in the presence of cat-
ions (Table 1). The presence of the strong K-helix destabilizing
Pro residue in the middle of the sequence not only causes a
major disruption in the K-helical backbone, but likely also
induces new local conformations in con-G.
A report has been published regarding the NMDA receptor
antagonist and conformational properties of a series of con-G
derived peptides that contained single amino acid replace-
ments at each of the ¢ve Gla residues [20]. These included
¢ve Ala peptides that are also included in the present study.
The NMDA antagonist activity of these peptides was also
determined in this case by measuring the inhibition of the
spermine enhanced [3H]MK-801 binding to rat brain mem-
branes. The observed IC50 values for the identical molecules
are very similar in both of these studies. Our IC50 values are
consistently about two-fold higher, most likely due to minor
di¡erences in assay conditions and/or membrane prepara-
tions.
Results of the present study also parallel an earlier report
on Gla to Ala replacement variants of con-T [8]. That study
also identi¢ed Gla3 and Gla4 as the only important bioactivity
determinants out of the four Gla residues present in con-T.
This correlation, along with the very similar pharmacology,
wild-type IC50 values, and high chemical homology of the two
conantokin peptides, suggests that they have a common mode
of action in the inhibition of the NMDA receptor, despite
major di¡erences in the conformations adopted by their
apo-forms [7,8].
In order to examine the conformational properties of the
con-G analogues in greater detail, the secondary structure of
each variant was determined by CD spectroscopy both in the
absence of multivalent metal ions and in the presence of either
Ca2 or Mg2. The Mg2-dependent K-helicity values were
determined at 1.5 mM Mg2, a concentration that is compa-
rable to the physiological concentration of this ion. Based on
considerations of binding a⁄nities and physiologically avail-
able free concentrations of multivalent metal ions, the conan-
tokins exist in Mg2 and/or Zn2 bound states [4,5]. Maximal
K-helicities obtainable in the presence of Zn2 were always
very close to the Mg2 values, and, therefore, only the latter
are reported.
Almost all con-G variants exhibited the cation-dependent
conformational change, although maximal helicity values var-
ied. There was no strict correlation observed between K-hel-
icity of the conantokin analogues in solution and their abil-
ities to inhibit MK-801 binding to the NMDA receptor.
Several peptides have decreased ability to adopt the K-helical
conformation when cations are added, but display wild-type-
like IC50 values. These variant peptides include con-G[Gla7A],
con-G[Gla7K] and con-G[Gla14A]. Several peptide variants
with substantially reduced potency possess an K-helical secon-
dary structure content that is comparable to the above men-
tioned fully active molecules. Con-G[Gla7;10;14E], a peptide
with a complete lack of secondary structure in the presence
of metal cations, possesses an IC50 that is only 10-fold higher
than its wild-type counterpart.
An illustrative summary of the importance of each con-G
residue in its NMDA antagonist activity is provided in Fig. 3.
Residues indicated in red lead to a very substantial loss of
activity when replaced by Ala. Due to the high extent of their
involvement in this property, we propose that these residues
directly interact with the binding site for con-G on the
NMDA receptor. Considering that both con-G and con-T
exist essentially in end-to-end K-helical conformations under
physiological conditions of cation concentrations, this model
for the interaction interface between con-G and its binding
site seems very plausible, as all of the essential residues are
clustered on a well de¢ned surface area comprising of the
N-terminal turn and one side of the K-helix along Leu5,
Gln9 and Ile12. All of the synthetic con-G analogues that
retained NMDA receptor inhibitory activity possess con-
siderable K-helix forming capabilities. The only exception
from this observation seems to be con-G[Gla7;10;14E]. This
peptide is in a random conformation at close to physiological
solution conditions. Its 10-fold decreased potency can result
from receptor-facilitated folding of this peptide, after initial
contact by critical amino acid residues. Further support for
this consideration is provided by the fact that the introduction
of the K-helix breaker Pro at position 7 leads to a complete
loss of activity. The L-turn-favoring Pro residue e¡ectively
prevents the receptor-induced K-helix formation in the region
important for binding, although otherwise this peptide, like
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con-G[Gla7;10;14E], possesses every amino acid side chain that
was identi¢ed as required or important in the NMDA recep-
tor antagonist activity of con-G.
In summary, individual amino acids of con-G have been
examined in order to identify those that play a critical role
in the NMDA receptor antagonist activity of this natural
molecule. Five residues, Glu2, Gla4, Leu5, Gln9, and Ile12,
have proven to be required for activity. In addition, four
additional amino acids, Gly1, Gla3, Leu11, and Arg13,
showed additional contributions, whereas the remainder of
the side chains of this 17-amino acid peptide is not impor-
tant in its inhibition of the NMDA receptor. Overall, we
have demonstrated that the K-helix forming capabilities of
most of the variant peptides are not compromised signi¢-
cantly with alterations in individual residues. However, ex-
ceptions are observed with peptides that are missing one or
both of Gla10 and Gla14, in that these variants have low
maximal metal ion bound K-helicity. These two amino acids
have been identi¢ed as the contributors of the primary metal
ion binding site in both con-G and con-T [7,8]. Based on
these bioassay results, it would appear that an intact metal
binding site at this locus is not an absolute requirement for
the neuroactivity of the conantokins, although such a metal
binding site does provide an increased rigidity to these short,
otherwise unconstrained peptides. Alternatively, the signi¢-
cance of metal binding and higly K-helical conformations
of wild-type conantokins may lie in advantages other than
increased receptor a⁄nity, such as increased half-life in both
the venom duct and in the body of the prey, solubility and
di¡usion parameters, or processing subsequent to post-trans-
lational modi¢cations.
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